



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Original article

Design and evaluation of an AFLP molecular marker for the detection of *Coccidioides* spp. in biological samples



María del Rocío Reyes-Montes^a, María Guadalupe Frías-De-León^b, Isai Victoriano-Pastelín^a, Gustavo Acosta-Altamirano^b, Esperanza Duarte-Escalante ^{a,*}

^a Facultad de Medicina (UNAM), Departamento de Microbiología y Parasitología, Laboratorio de Micología Molecular, Ciudad de México, Mexico

^b Hospital Regional de Alta Especialidad de Ixtapaluca, Dirección de Investigación, Ixtapaluca, Mexico

ARTICLE INFO

Article history:

Received 10 April 2019

Accepted 16 August 2019

Available online 17 September 2019

Keywords:

Molecular markers

SCAR

Coccidioidomycosis

Coccidioides spp.

ABSTRACT

At present, there is no standardized marker that is routinely used in clinical laboratories to diagnose coccidioidomycosis. Thus, the goals of this study were to obtain a sequence characterized amplified region (SCAR) marker for the identification of *Coccidioides* spp., evaluate its specificity and sensitivity in fungal DNA-spiked blood and sputum samples, and compare it with previously described molecular markers. Specific amplified fragment length polymorphism (AFLP) amplicons for *Coccidioides immitis* and *Coccidioides posadasii* were cloned into the vector pGEM® -T Easy vector and sequenced to develop a SCAR marker. Oligonucleotides were designed to identify *Coccidioides* spp. by polymerase chain reaction (PCR), and the specificity and sensitivity of these oligonucleotides were tested with the DNA from related pathogens. The specificity and sensitivity of the SCAR marker was evaluated with blood and sputum samples spiked with *Coccidioides* DNA and compared with other previously described markers (621, GAC2, and Ag2/PRA). In addition, the conditions for its use were established using biological samples. A specific marker named SCAR₃₀₀ was obtained to identify *Coccidioides* spp. that exhibited good sensitivity and specificity. The results showed that all of the markers tested in this study can identify *Coccidioides* spp. However, the SCAR₃₀₀ and 621 markers were the most sensitive, whereas the SCAR₃₀₀ marker was the most specific. Thus, the SCAR₃₀₀ marker is a useful tool to identify *Coccidioides* spp.

© 2019 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The fungi *Coccidioides immitis* and *Coccidioides posadasii* are the causative agents of coccidioidomycosis,¹ a predominant disease in the Americas. The areas most affected by this mycosis

* Corresponding author.

E-mail address: dupe@unam.mx (E. Duarte-Escalante).

<https://doi.org/10.1016/j.bjid.2019.08.002>

1413-8670/© 2019 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

are endemic areas of the Southwestern United States of America (USA),² northern Mexico, some Central America regions³ and South America.^{4,5} Although most infections caused by these fungi are asymptomatic, some can develop into symptomatic clinical infections with mild respiratory symptoms or may develop into severe disseminated infections that are typically associated with Aids or HIV-infected patients, individuals having received transplants, hemodialysis patients, cancer patients undergoing treatment (primarily Hodgkin's lymphoma), pregnant women, or individuals with diabetes or tuberculosis.^{6,7}

The number of coccidioidomycosis cases in the USA has increased in recent years.⁸ However, the number of cases in Mexico is unknown, as coccidioidomycosis ceased to be a notifiable disease in 1994, although it has been suggested that the same trend is occurring.⁹

The diagnosis of this disease has traditionally been based on the results of a combination of clinical data, the isolation of the causative agent in clinical samples, and imaging studies. However, since the causative fungi grow slowly, rapid methods for its identification are required, such as conventional serological techniques, although these methods also have limitations.¹⁰ For this reason, molecular techniques that use different polymerase chain reaction (PCR) markers have been developed in recent years.^{11–18} However, these techniques have not yet had a significant impact on the majority of clinical laboratories in the diagnosis of coccidioidomycosis. Thus, other identification strategies have been developed, one of which is the use of the so-called SCAR (sequence characterized amplified region) markers, which have been useful for studying variation among organisms, identifying strains of interest, determining the origin of isolates, studying population structure, and detecting pest resistance genes.¹⁹ SCAR markers have also been used for diagnostic and epidemiological application in other human pathogenic fungi, such as *Histoplasma capsulatum*,²⁰ demonstrating its usefulness for the identification of specific microorganisms. Therefore, the aim of this study was to obtain a SCAR marker from polymorphic patterns obtained from amplified fragment length polymorphism (AFLP) to identify *Coccidioides* spp., in addition to evaluate its specificity and sensitivity in fungal DNA-spiked blood and sputum samples. Furthermore, we compared the SCAR marker to three previously described molecular markers and established the conditions for its use in biological samples.

Material and methods

Isolates

A total of 40 isolates were included in this study (Table S1), including four isolates from Mexico that were previously identified as *C. immitis* and 36 identified as *C. posadasii*, of which 25 were isolated in Mexico and 11 in Argentina.²¹ All of the isolates were cultured in tubes containing Mycobiotic agar® (BD Bioxon, Estado de México, México) and were incubated at 28 °C for five days or until good growth was observed for subsequent trials.

Biological samples

Whole blood and sputum samples used in this study were obtained from a healthy human volunteer.

DNA extraction from *C. immitis* and *C. posadasii* isolates

All of the *C. immitis* and *C. posadasii* isolates included in the study were grown in YPD medium (10% yeast extract, 10% peptone, and 20% dextrose) for 7–10 days at 28 °C. DNA extraction was performed as described by Duarte-Escalante et al.²¹ The DNA concentration was determined via spectrophotometry (Spectrophotometer DS-11, DeNovix, Delaware, USA), and the DNA samples were stored at 4 °C until use.

The DNA from *Sporohrix schenckii* was kindly provided by Conchita Toriello (Facultad de Medicina, UNAM, Mexico), *Candida glabrata*, was kindly provided by María Guadalupe Frías De León (Hospital Regional de Alta Especialidad de Ixtapaluca, México), *Histoplasma capsulatum* was kindly provided by María Lucia Taylor (Facultad de Medicina, UNAM, Mexico), *Aspergillus fumigatus* and *A. niger* were kindly provided by María del Rocío Reyes Montes (Facultad de Medicina, UNAM, Mexico), and *Mycobacterium tuberculosis* was kindly provided by Miriam Bobadilla del Valle (Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico). DNA from all of the fungi tested, as well as from *M. tuberculosis*, was used to check the specificity of the *Coccidioides* spp. molecular markers studied.

Obtaining of the SCAR marker: AFLP and SCAR marker selection

The AFLP assays were performed according to Duarte-Escalante et al.,²¹ using six selective primer combinations: E + AA:M + CAC, E + AA:M + CAT, E + AA:M + CTG, E + AA:M + CTC, E + AC:M + CAT and E + AC:M + CTC. The analysis of the polymorphic patterns obtained through AFLP with the six combinations of oligonucleotides allowed the identification of a band common in all isolates, of 300 bp with the combination E + AC/M + CAT. The specific DNA fragment of *Coccidioides* spp. were purified using a QIAquick gel extraction kit (Qiagen, Inc., Valencia, California, USA) and cloned into the pGEM-T Easy vector (Promega, Madison, WI, USA), according to Frías De León et al.²⁰ The SCAR marker was sequenced at the Unidad de Biología Molecular, Instituto de Fisiología Celular, UNAM, using an ABI Prism 3100 automated DNA sequencer (Applied Biosystems, Inc., Foster City, CA, USA). The SCAR marker sequences were analyzed using BLAST²² to verify similarities between all of the fungal sequences deposited in the database. A specific sequence of the fungus which had no coincidence whatsoever with the sequences of related fungi deposited in the GenBank was selected to design the specific nucleotides for *Coccidioides* spp. Oligonucleotides were designed based on the SCAR sequence using Primer3 (<http://frodo.wi.mit.edu/cgi-bin/primer3/primer3-www.cgi>) and were synthesized by Sigma-Genosys (The Woodlands, Texas, USA). The PCR with the SCAR marker conditions were established with the 40 DNA preparations obtained from *C. immitis* and *C. posadasii*.




Fig. 1 – Sensitivity of the SCAR₃₀₀ marker. PCR was performed with different DNA concentrations of the *C. posadasii* (HU-1) reference strain, as described in the Materials and Methods section. Positive control (+); negative control (-); bp (molecular size marker).

Evaluation of the sensitivity and specificity of the SCAR, Ag2/PRA, and microsatellite 621 and GAC2 markers

The sensitivity of the SCAR marker and that of the Ag2/PRA and microsatellite 621 and GAC2 markers was determined using different concentrations of DNA from the *C. posadasii* reference strain (HU-1).

The specificities of the SCAR, Ag2/PRA,¹¹ GAC2,¹ and 621¹ markers were evaluated using DNA from the *C. posadasii* reference strain (HU-1) and that of other pathogens that cause clinical symptoms similar to *Coccidioides* spp. (*A. niger*, *A. fumigatus*, *H. capsulatum*, *S. schenckii*, *C. glabrata*, and *M. tuberculosis*).

Evaluation of the SCAR, Ag2/PRA, and microsatellite GAC2 and 621 markers in blood and sputum samples spiked with *C. posadasii* DNA (HU-1)

Five hundred microliters of blood or sputum was spiked with 30 µL of *C. posadasii* DNA (HU-1) at different concentrations (2.83×10^2 , 2.83×10^1 , 2.83×10^0 , 2.83×10^{-1} , 2.83×10^{-2} , 2.83×10^{-3} , 2.83×10^{-4} , 2.83×10^{-5} , and 2.83×10^{-6} ng/µL). Each tube was processed to obtain total DNA using a DNeasy Blood & Tissue Kit (Qiagen).

All PCR assays were performed in a total volume of 50 µL with 5, 10, 15, and 20 µL of total DNA obtained from blood or sputum samples spiked with *C. posadasii* DNA (HU-1). The PCR conditions used for each marker were the same as those described above.

Results

Obtaining of the SCAR marker: selection of AFLP bands for the SCAR marker

Analysis of the polymorphic patterns obtained by AFLP with the six combinations of selective oligonucleotides used resulted in the identification of differential bands between *C. posadasii* and *C. immitis*. Four differential bands were obtained for *C. posadasii*: a 250-bp band obtained with the E + AA/M + CTC combination; two bands, a 150-bp band and a 300-bp band, obtained with the E + AC/M+CAT combination; and a 180-bp band obtained with the E + AA/M + CAT

combination, as well as a 200-bp differential band obtained with the E + AA/M + CAT combination. All of the bands were reamplified under the same conditions in which they were generated. The fragments were cloned into the vector pGEM®-T Easy and the presence of the inserts was corroborated by colony PCR with the left and right universal oligonucleotides pUC/M13 and subsequently by restriction digest analysis, which revealed the expected size for each fragment. Only the 300-bp sequence showed 100% identity with *C. immitis* and *C. posadasii* with the sequences deposited in GenBank, whereas the sequences of the 250-, 180-, and 150-bp bands showed no identity with *Coccidioides* spp. sequences. The 300-bp sequence was subsequently named SCAR₃₀₀.

Oligonucleotide design for the identification of *Coccidioides* spp.

Using the SCAR₃₀₀ marker, the specific oligonucleotides SCAR₃₀₀ (F) (5'-AATGGCGTTAACAGTGGGTC-3') and SCAR₃₀₀ (R) (5'-AAGCCACTTACACAATCCAG-3') were designed. PCR was performed in a 25-µL reaction containing 10 ng of DNA, 2.0 mM MgCl₂, 200 µM deoxynucleotide triphosphates (Applied Biosystems, Foster City, California, USA), 0.1 nmol of each oligonucleotide (SCAR₃₀₀-F and SCAR₃₀₀-R), and 1 U of Taq DNA polymerase (Applied Biosystems) in 1 × PCR buffer (Applied Biosystems). The amplification conditions were as follows: one cycle at 94°C for 5 min; 30 cycles at 94°C for 30 s, 53°C for 30 s, 72°C for 1 min; and a final extension at 72°C for 5 min. Gel electrophoresis was performed in a 1% agarose gel with 0.5× Tris-borate-EDTA at 100 V.

Evaluation of the sensitivity and specificity of the SCAR, Ag2/PRA, and microsatellite 621 and GAC2 markers

The minimum amount of DNA detected by PCR using the SCAR₃₀₀ marker was 1 ng/µL (Fig. 1).

The SCAR₃₀₀ marker was amplified using the *C. posadasii* (HU-1) DNA and exhibited the expected 300-bp product, whereas no amplification was observed using the DNA from the other assayed pathogenic fungi and *M. tuberculosis* (Fig. 2A). The expected 400-bp product was amplified for the 621 microsatellite using the *C. posadasii* (HU-1) DNA, whereas




Fig. 2 – Specificity of the molecular markers for the detection of *Coccidioides* spp. (A) SCAR₃₀₀, (B) 621, GAC2 and (C) Ag2/PRA. The specificities of the molecular markers were determined as described in the Materials and Methods section using DNA from other pathogenic fungi and *M. tuberculosis*. Positive control (+); negative control (−); bp (molecular size marker).

no amplification was observed using DNA from the other pathogenic fungi (Fig. 2B). The expected 200-bp fragment was amplified for the GAC2 microsatellite using the *C. posadasii* (HU-1) DNA, although additional products of different sizes were amplified when DNA from *A. fumigatus*, *H. capsulatum*,

A. niger, *S. schenckii*, and *M. tuberculosis* was used (Fig. 2B). In addition, the expected 300-bp amplicon was obtained for the Ag2/PRA marker using *C. posadasii* (HU-1) DNA, although a 200-300-bp product was also amplified using *S. schenckii* DNA (Fig. 2C).

Evaluation of the SCAR, Ag2/PRA, and microsatellite GAC2 and 621 markers in blood and sputum samples spiked with *C. posadasii* DNA (HU-1)

Evaluation of the SCAR₃₀₀ marker using blood and sputum samples

The concentrations of total DNA obtained from blood and sputum samples spiked with *C. posadasii* (HU-1) DNA were 10–100 and 50–100 ng/μL, respectively. The expected 300-bp band was observed when 10, 15, and 20 μL of total DNA was used from the blood spiked with 2.83×10^1 to 2.83×10^{-1} ng/μL of Coccidioides DNA, while the band was detected when 5 μL of total DNA was used from blood spiked with 2.83×10^1 ng/μL of Coccidioides DNA (Fig. 3). In contrast, for the sputum samples, the 300-bp band was observed when 5 and 15 μL of total DNA was used from sputum spiked with 2.83×10^1 to 2.83×10^0 ng/μL of Coccidioides DNA, while the amplicon was observed when 10 and 20 μL of total DNA was used from sputum spiked with 2.83×10^1 to 2.83×10^{-1} ng/μL of Coccidioides DNA (Fig. 4).

Evaluation of the GAC2 and 621 microsatellites in blood and sputum samples

When blood or sputum that was spiked with different concentrations of Coccidioides DNA harboring the GAC2 microsatellite was assayed for this marker by PCR, the expected 200-bp band was observed when five and 10 μL of total DNA was used from blood spiked with 2.83×10^1 to 2.83×10^{-6} and 2.83×10^1 to 2.83×10^{-1} ng/μL of Coccidioides DNA, respectively. In addition, the expected amplicon was observed when 15 and 20 μL of total DNA was used from blood spiked with 2.83×10^1 to 2.83×10^{-2} ng/μL of Coccidioides DNA (Fig. 3). For the sputum, a 200-bp amplicon was observed when 20 μL of total DNA was used from sputum spiked with 2.83×10^1 to 2.83×10^0 of Coccidioides DNA, while the expected band was observed when 5, 10, and 15 μL of total DNA was used from sputum spiked with 2.83×10^1 to 2.83×10^{-1} ng/μL of Coccidioides DNA (Fig. 4).

The 400-bp 621 microsatellite amplicon was observed when 5 μL of total DNA was used from blood spiked with 2.83×10^1 to 2.83×10^{-1} ng/μL of Coccidioides DNA, while the expected amplicon was observed when 10 μL of total DNA was used from blood spiked with 2.83×10^1 to 2.83×10^{-7} ng/μL of Coccidioides DNA. In contrast, the 400-bp amplicon was observed when 15 and 20 μL of total DNA was used from blood spiked with 2.83×10^1 to 2.83×10^{-3} and 2.83×10^1 to 2.83×10^{-2} ng/μL of Coccidioides DNA, respectively (Fig. 3). For the sputum samples, the 400-bp amplicon was observed when 5 and 10 μL of total DNA was used from sputum spiked with 2.83×10^1 to 2.83×10^{-7} and 2.83×10^1 to 2.83×10^{-6} ng/μL of Coccidioides DNA, respectively. In contrast the expected amplicon was observed when 15 and 20 μL of total DNA was used from sputum spiked with 2.83×10^1 to 2.83×10^{-3} ng/μL and 2.83×10^1 to 2.83×10^{-2} ng/μL of Coccidioides DNA, respectively (Fig. 4).

Evaluation of the Ag2/PRA marker with blood and sputum samples

For the Ag2/PRA marker, the 300-bp band was observed when 5, 10, and 15 μL of total DNA was used from blood spiked with 2.83×10^1 to 2.83×10^0 ng/μL of Coccidioides DNA. In contrast, the expected amplicon was

observed when 20 μL of total DNA was used from blood spiked with 2.83×10^1 to 2.83×10^{-1} ng/μL of Coccidioides DNA (Fig. 3). For the sputum samples, the 300-bp band was observed when 5, 10, 15, and 20 μL of total DNA was used from sputum spiked with 2.83×10^1 to 2.83×10^{-5} , 2.83×10^1 to 2.83×10^{-3} ng/μL, 2.83×10^1 to 2.83×10^{-7} ng/μL, and 2.83×10^1 to 2.83×10^{-2} ng/μL of Coccidioides DNA, respectively (Fig. 4).

Discussion

Various molecular markers have been described for the identification of *Coccidioides* spp. for diagnostic and epidemiological purposes.^{1,11,13,15,16,23} However, many of these markers have low sensitivity, specificity, and reproducibility as well as limitations associated with complicated methodologies that involve high costs. A small number of markers have been obtained from ribosomal genes, which are naturally conserved within the fungal kingdom; however, their use can lead to nonspecific results among several fungal species.^{24,25} In addition, commercially available probes used for diagnostic tests also yield nonspecific results in some cases.²⁶ Due to these drawbacks, designing more specific and sensitive markers for the identification of *Coccidioides* was necessary. SCAR markers have been designed for other pathogenic fungi and are excellent candidates for this purpose, as described by Frías De León et al.²⁰ Due to their high specificity and sensitivity, molecular methods are gradually being implemented as routine methods in clinical laboratories to confirm the information obtained through conventional methods. Furthermore, these newer techniques are used as auxiliary methods in the diagnosis of questionable cases of some mycoses as well as to facilitate the characterization of infection sources and to consolidate epidemiological information of such mycoses, especially in Latin American countries.

SCAR markers have proven to be very useful, with the development of a SCAR marker requiring the use of two specific primers that are designed from the nucleotide sequences of amplicons generated using techniques such as random amplification of polymorphic DNA (RAPD) or AFLP, after which they are cloned and associated with a feature of interest. Once developed, a SCAR marker can be applied to a large number of samples that can be simultaneously examined, reducing the necessary time and increasing reliability.²⁷

It is important to mention that the development of molecular markers from native isolates, as is the case of the SCAR₃₀₀ marker, is very important, since great genetic variability has been observed in isolates of *C. immitis* and *C. posadasii* from different geographic origins.^{24,28-30} Furthermore, it has been suggested that molecular markers used to detect pathogens from clinical samples should be designed from native isolates in the region in which they are to be used. Thus, it is important that the SCAR₃₀₀ marker be validated for use in these countries.

Although one of the objectives of the present study was to design specific SCAR markers that were for *C. immitis* and *C. posadasii*, this was not possible due to the small number of isolates belonging to the *C. immitis* species and because of the high diversity found in all isolates, which made it difficult




Fig. 3 – Sensitivity of the SCAR₃₀₀, 621, GAC2, and Ag2/PRA markers. Different volumes (5, 10, 15, and 20 μ L) of total DNA obtained from blood spiked with different concentrations of *C. posadasii* reference strain (HU-1) DNA were used. Positive control (+); negative control (-); bp (molecular size marker).

to identify species-specific bands in the polymorphic patterns obtained by AFLP. Thus, the designed marker was specific only at the genus level. However, because the SCAR₃₀₀ marker was

tested using isolates from Mexico and Argentina and showed good specificity and sensitivity, it may be a good candidate for the identification of fungi of the genus *Coccidioides*. However,




Fig. 4 – Sensitivity of the SCAR₃₀₀, 621, GAC2, and Ag2/PRA markers. Different volumes (5, 10, 15, and 20 μ L) of total DNA obtained from sputum spiked with different concentrations of *C. posadasii* reference strain (HU-1) DNA were used. Positive control (+); negative control (-); bp (molecular size marker).

it is necessary that the marker be evaluated with clinical samples and samples obtained from different sources of infection.

The results of this study showed that the SCAR₃₀₀ marker was efficient at amplifying *Coccidioides* DNA from biological

samples (blood or sputum) experimentally spiked with different concentrations of HU-1 strain DNA, even though it showed lower sensitivity than the GAC2 and 621 microsatellites.¹ The SCAR₃₀₀ marker was also shown to have a sensitivity that

is highly similar to that of the marker Ag2/PRA, confirming its usefulness as a diagnostic tool for coccidioidomycosis (Fig. 3 and 4).

Regarding the specificity of the SCAR₃₀₀ marker, it was shown to be as specific as the 621 microsatellite marker, since both were only amplified using DNA from *C. posadasii*. In contrast, in addition to DNA from *C. posadasii*, the GAC2 microsatellite was amplified using DNA from *A. fumigatus*, *A. niger*, *H. capsulatum*, *S. schenckii*, and *M. tuberculosis*, whereas the Ag2/PRA marker was amplified using DNA from *C. posadasii* and *S. schenckii*, making both of these markers less efficient for use in the diagnosis of coccidioidomycosis.

According to the results obtained in the present study with respect to the use of different volumes of total DNA (biological sample spiked with DNA from the HU-1 isolate), the use of 10 and 15 µL of total DNA from blood and sputum is recommended for the PCR with SCAR₃₀₀ marker. This information is useful as a guide for laboratory personnel in charge of performing molecular diagnosis, since these results indicate the minimum volume of total sample DNA needed to perform PCR and achieve a positive result.

Conclusions

Although the 621 microsatellite marker showed greater sensitivity than the SCAR₃₀₀ marker, it is important to note that the latter presents the advantage of having been obtained from isolates from Mexico and Argentina, which ensures the detection of the fungus in these countries.

However, it is essential that the SCAR₃₀₀ marker, which was tested in this study using biological samples spiked with DNA from a *C. posadasii* isolate (HU-1), be tested with the largest possible number of clinical samples from patients with suspected coccidioidomycosis to definitively validate the method and corroborate its diagnostic utility.

Conflict of interest

All the authors of this study declare the absence of any potential conflicts of interest.

Acknowledgements

This work was financially by PAPIIT-DGAPA (IN215509-3).

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.bjid.2019.08.002>.

REFERENCES

1. Fisher MC, Koenig GL, White TJ, Taylor JW. Molecular and phenotypic description of *Coccidioides posadasii* sp. nov. previously recognized as the non-California population of *Coccidioides immitis*. *Mycologia*. 2002;94:73–84.
2. Fisher FS, Bultman MW, Johnson SM, Pappagianis D, Zaborsky E. Coccidioides niches and habitat in the Southwestern United States: a matter of scale. *Ann NY Acad Sci*. 2007;1111:47–72.
3. Laniado-Laborín R. Expanding understanding of epidemiology of coccidioidomycosis in the Western hemisphere. *Ann NY Acad Sci*. 2007;1111:19–34.
4. Canteros CE, Toranzo A, Ibarra-Camou B, et al. La coccidioidomicosis en Argentina, 1892–2009. *Rev Arg Microbiol*. 2010;42:261–8.
5. de Aguiar Cordeiro R, Nogueira-Brilhante RS, Marcos Fábio Gadelha Rocha MF, et al. Twelve years of coccidioidomycosis in Ceará State, Northeast Brazil: epidemiologic and diagnostic aspects. *Diagn Microbiol Infect Dis*. 2010;6:65–72.
6. Laniado-Laborín R, Alcantar-Schramm JM, Cazares-Adame R. Coccidioidomycosis: an update. *Curr Fungal Infect Rep*. 2012;6:113–20.
7. Laniado-Laborín R, Arathoon EG, Canteros C, Muñiz-Salazar R, Rendon A. Coccidioidomycosis in Latin America. *Med Mycol*. 2019;57:S46–55.
8. Sondermeyer GL, Lee LA, Gilliss D, Vugia DJ. Coccidioidomycosis-associated deaths in California, 2000–2013. *Public Health Rep*. 2016;131:531–5.
9. Baptista-Rosas RC, Riquelme M. Epidemiología de la coccidioidomicosis en México. *Rev Iberoam Micol*. 2007;24:100–6.
10. Negroni R, Arechavala A, Maiolo E. Coccidioidomycosis. *Med Cutan Iber Lat Am*. 2010;38:179–88.
11. Bialek R, Kern J, Herrmann T, et al. PCR assays for identification of *Coccidioides posadasii* based on the nucleotide sequence of the antigen 2/proline-rich antigen. *J Clin Microbiol*. 2004;42:778–83.
12. Assi MA, Binnicker MJ, Wengenack NL, Deziel PJ, Badley AD. Disseminated coccidioidomycosis in a liver transplant recipient with negative serology: use of polymerase chain reaction. *Liver Transpl*. 2006;12:1290–2.
13. Umezawa T, Sano A, Kamei K, Niimi M, Nishimura K, Uehara Y. Novel approach to design primers for identification and distinction of the human pathogenic fungi *Coccidioides immitis* and *Coccidioides posadasii* by PCR amplification. *J Clin Microbiol*. 2006;44:1859–62.
14. Pounder JL, Hansen D, Woods GL. Identification of *Histoplasma capsulatum*, *Blastomyces dermatitidis*, and *Coccidioides* species by repetitive sequence based PCR. *J Clin Microbiol*. 2006;44:2977–82.
15. Binnicker MJ, Buckwalter SP, Eisbrenner JJ, et al. Detection of *Coccidioides* species in clinical specimens by real-time PCR. *J Clin Microbiol*. 2007;45:173–8.
16. Tintelnot K, De Hoog GS, Antweiler E, et al. Taxonomic and diagnostic markers for identification of *Coccidioides immitis* and *Coccidioides posadasii*. *Med Mycol*. 2007;45:385–93.
17. Duarte-Escalante E, Frías-De-León MG, Zúñiga G, et al. Molecular markers in the epidemiology and diagnosis of coccidioidomycosis. *Rev Iberoam Micol*. 2014;31:49–53.
18. Johnson L, Gaab ME, Sanchez J, et al. Valley Fever: Danger lurking in a dust cloud. *Microbes Infect*. 2014;16:591–600.
19. Xu M, Korban SS. AFLP-derived SCARs facilitate construction of a 1.1 Mb sequence-ready map of a region that spans the *Vf* locus in apple genome. *Plant Mol Biol*. 2003;50:803–18.
20. Frías-De-León MG, Arenas-López G, Taylor ML, Acosta-Altamirano G, Reyes-Montes MR. Development of specific SCAR markers for detecting *Histoplasma capsulatum* in clinical and environmental samples. *J Clin Microbiol*. 2012;50:673–9.
21. Duarte-Escalante E, Zúñiga G, Frías-De-León MG, Canteros C, Castañón-Olivares LR, Reyes-Montes MR. AFLP analysis reveals high genetic diversity but low population structure in *Coccidioides posadasii* isolates from Mexico and Argentina. *BMC Infect Dis*. 2013;13:411.

22. Altschul S, Madden T, Shäffer A, Zhang J, Miller W, Lipman A. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 1997;25:3389–402.
23. Greene DR, Koenig G, Fisher MC, Taylor JW. Soil isolation and molecular identification of *Coccidioides immitis*. *Mycologia*. 2000;92:406–10.
24. Lindsley MD, Hurst SF, Nauren JI, Morrison CJ. Rapid identification of dimorphic and yeast-like fungal pathogens using specific DNA probes. *J Clin Microbiol.* 2001;39:505–11.
25. Martagon Villamil J, Shrestha N, Sholtis M, et al. Identification of *Histoplasma capsulatum* from culture extracts by real-time PCR. *J Clin Microbiol.* 2003;41:1295–8.
26. Brandt ME, Gaunt D, Iqbal N, McClinton S, Hambleton S, Sigler L. False-positive *Histoplasma capsulatum* Gen-Probe chemiluminescent test result caused by a *Chrysosporium* species. *J Clin Microbiol.* 2005;43:1456–8.
27. Bhagyawant SS. RAPD-SCAR markers: an interface tool for authentication of traits. *J Biosci Med.* 2016;4:1–9.
28. Koufopanou V, Burt A, Taylor JW. Concordance of gene genealogies reveals reproductive isolation in the pathogenic fungus *Coccidioides immitis*. *Proc Natl Acad Sci USA.* 1997;94:5478–82.
29. Fisher MC, Koenig GL, White TJ, Taylor JW. A test for concordance between the multilocus genealogies of genes and microsatellites in the pathogenic fungus *Coccidioides immitis*. *Mol Biol Evol.* 2000;17:1164–74.
30. Jewell K, Cheshire R, Cage GD. Genetic diversity among clinical *Coccidioides* spp. isolates in Arizona. *Med Mycol.* 2008;46:449–55.